For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Independent experts to follow up ACC as it reassesses declined mesh-injury claims
This story has been updated from the print version to include the most recent data from ACC
+News
In print
Independent experts to follow up ACC as it reassesses declined mesh-injury claims
Monday 3 May 2021, 04:35 PM

Mesh Down Under team members Charlotte Korte, Carmel Berry and Patricia Sullivan are pleased to see ACC decisions will be monitored
Zahra Shahtahmasebi catches up on latest moves to resolve concerns about compensation for injuries sustained by patients who have had surgical mesh inserted
Key points, ACC has accepted lobby group Mesh Down Under’s recommendation to allow an independent medicolegal panel to oversee its reassessment of declined claims
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.